Tenaya Therapeutics Inc.

AI Score

0

Unlock

1.44
-0.06 (-4.00%)
At close: Jan 14, 2025, 3:59 PM
1.47
2.08%
Pre-market Jan 15, 2025, 06:25 AM EST
undefined%
Bid 1.47
Market Cap 114.08M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.44
PE Ratio (ttm) -1
Forward PE n/a
Analyst Buy
Ask 1.48
Volume 1,683,758
Avg. Volume (20D) 5,017,749
Open 1.54
Previous Close 1.50
Day's Range 1.44 - 1.55
52-Week Range 0.99 - 7.01
Beta undefined

About TNYA

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mut...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 140
Stock Exchange NASDAQ
Ticker Symbol TNYA

Analyst Forecast

According to 4 analyst ratings, the average rating for TNYA stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 1150.00% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Tenaya Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025, during market hours.
Analysts project revenue of $1.00M, reflecting a n/a YoY growth and earnings per share of -0.4, making a 0.00% YoY.
4 weeks ago · Source
-51.04%
Tenaya Therapeutics shares are trading lower. The ... Unlock content with Pro Subscription
1 month ago · Source
+11.15%
Tenaya Therapeutics shares are trading higher after HC Wainwright & Co. reiterated a Buy rating on the stock and announced a price target of $18.